BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on ...

BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...

MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of ...

The self-regulatory body of the German communications industry has accused BioNTech of trying to pull out of a public debate about vaccine patents. BioNTech received the warning after it asked Twitter ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...

BioNTech may still claim that the bispecific antibody acasunlimab has an “encouraging” clinical profile, but the mRNA leader has opted to end its involvement and allow partner Genmab to go solo for ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stages ...

BioNTech has struck a deal to explore oral delivery of mRNA vaccines. Working with Matinas BioPharma, the German mRNA specialist will study the potential for a lipid nanocrystal (LNC) platform to ...

BioNTech (BNTX) shares have shown mixed momentum over the past month, with a modest recovery in the past week. Investors seem to be weighing the company’s recent performance as they consider its ...

BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to improve ...

(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...